Polycationic Structures for Non-Viral Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Non-viral gene delivery systems face limitations in achieving therapeutic protein expression levels and duration, particularly with systemic administration due to serum nucleases and low efficiency compared to viral or liposomal vectors, restricting their application to accessible tissues like skin and muscle.
Innovation Solution
The use of polycationic structures like empty cationic liposomes and CpG-free or CpG-reduced non-viral expression vectors, sequentially administered to achieve therapeutic protein expression for extended periods, overcoming the limitations of existing non-viral gene delivery systems by enhancing protein levels and duration of expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If naked expression vector DNA is used for direct injection, then the simplicity of the approach is improved, but the overall level of gene expression is much lower than with viral or liposomal vectors
Solution Approach 1:
The patent introduces polycationic structures as intermediary carriers that facilitate the delivery of naked expression vector DNA into cells. These polycationic structures act as mediators between the simple naked DNA and the cellular machinery, enabling efficient transfection without requiring complex viral or liposomal vectors, thus resolving the contradiction between simplicity and expression level.
Solution Approach 2:
The patent employs composite material systems combining polycationic structures with naked expression vector DNA to create a synergistic delivery system. This composite approach allows the simplicity of naked DNA to be preserved while achieving high gene expression levels through the enhancing effect of the polycationic carrier, effectively resolving the contradiction between operational simplicity and productivity.
2Ease of operation
If naked DNA is used for systemic administration, then the approach remains simple, but it is generally unsuitable due to the presence of serum nucleases
Solution Approach 1:
The polycationic structures serve as protective intermediaries that shield the naked expression vector DNA from serum nucleases during systemic administration. This intermediary carrier enables the DNA to survive in the circulation and reach target cells, making systematic administration reliable while maintaining the simplicity of using naked DNA vectors.
Solution Approach 2:
The patent applies preliminary protection by incorporating polycationic structures before administration to pre-protect the naked DNA from nuclease degradation. This preliminary action ensures the DNA remains intact during systemic transport, establishing reliability for systemic administration before the actual gene expression occurs.
3Ease of operation
If direct injection of plasmid DNA is used, then the approach is limited to accessible tissues, but the simplicity and ease of administration to those tissues is maintained
Solution Approach 1:
The patent makes the delivery system universal by incorporating polycationic structures that can facilitate naked DNA delivery across multiple tissue types and administration routes. This multi-functional carrier enables the simple naked DNA approach to work not only in accessible tissues like skin and muscle but also in other tissues through systemic administration, greatly enhancing adaptability while preserving ease of operation.
Data Source
AI summary
The present invention provides compositions, systems, kits, and methods for generating expression of one or more proteins and/or biologically active nucleic acid molecules in a subject (e.g., at therapeutic levels for extended periods required to produce therapeutic effects). In certain embodiments, systems and kits are provided that comprise a first composition comprising a first amount of polycationic structures, and a second composition comprising a therapeutically effective amount of expression vectors (e.g., non-viral expression vectors not associated with liposomes) that are CpG-free or CpG-reduced, where the expression vectors comprise a first nucleic acid sequence encoding: i) a first therapeutic protein or proteins, and/or ii) a first biologically active nucleic acid molecule or molecules.